These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30635889)

  • 1. p73-Governed miRNA Networks: Translating Bioinformatics Approaches to Therapeutic Solutions for Cancer Metastasis.
    Logotheti S; Marquardt S; Pützer BM
    Methods Mol Biol; 2019; 1912():33-52. PubMed ID: 30635889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness.
    Galtsidis S; Logotheti S; Pavlopoulou A; Zampetidis CP; Papachristopoulou G; Scorilas A; Vojtesek B; Gorgoulis V; Zoumpourlis V
    Cancer Lett; 2017 Mar; 388():96-106. PubMed ID: 27919789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.
    Vera J; Schmitz U; Lai X; Engelmann D; Khan FM; Wolkenhauer O; Pützer BM
    Cancer Res; 2013 Jun; 73(12):3511-24. PubMed ID: 23447575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p73: From the p53 shadow to a major pharmacological target in anticancer therapy.
    Ramos H; Raimundo L; Saraiva L
    Pharmacol Res; 2020 Dec; 162():105245. PubMed ID: 33069756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer.
    Hall C; Muller PAJ
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting p73--a potential approach in cancer treatment.
    Slade N; Horvat A
    Curr Pharm Des; 2011; 17(6):591-602. PubMed ID: 21391909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy.
    Sargolzaei J; Etemadi T; Alyasin A
    Pharmacol Res; 2020 Oct; 160():105179. PubMed ID: 32890739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
    Boominathan L
    Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dominant-negative interplay between p53, p63 and p73: A family affair.
    Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
    Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 family members and chemoresistance in cancer: what we know and what we need to know.
    Gasco M; Crook T
    Drug Resist Updat; 2003 Dec; 6(6):323-8. PubMed ID: 14744496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p53/microRNA network in cancer: experimental and bioinformatics approaches.
    Hünten S; Siemens H; Kaller M; Hermeking H
    Adv Exp Med Biol; 2013; 774():77-101. PubMed ID: 23377969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells.
    Dabiri Y; Kalman S; Gürth CM; Kim JY; Mayer V; Cheng X
    Sci Rep; 2017 Jul; 7(1):5423. PubMed ID: 28710427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
    Murray-Zmijewski F; Lane DP; Bourdon JC
    Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of p73 and p53 regulation and effector functions.
    Fang L; Lee SW; Aaronson SA
    J Cell Biol; 1999 Nov; 147(4):823-30. PubMed ID: 10562283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA and cancer; computational and experimental approaches.
    Tutar Y
    Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulating the genome surveillance system: miRNAs and the p53 super family.
    Bailey SG; Sanchez-Elsner T; Stephanou A; Cragg MS; Townsend PA
    Apoptosis; 2010 May; 15(5):541-52. PubMed ID: 20091234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
    Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
    Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis.
    Shirjang S; Mansoori B; Asghari S; Duijf PHG; Mohammadi A; Gjerstorff M; Baradaran B
    Free Radic Biol Med; 2019 Aug; 139():1-15. PubMed ID: 31102709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Wang YW; Zhang W; Ma R
    Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.